Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1953 1
1954 1
1955 1
1957 1
1960 3
1961 3
1962 8
1963 7
1964 9
1965 7
1966 17
1967 13
1968 12
1969 25
1970 21
1971 19
1972 15
1973 13
1974 13
1975 20
1976 33
1977 26
1978 39
1979 34
1980 29
1981 50
1982 39
1983 49
1984 48
1985 68
1986 63
1987 63
1988 67
1989 77
1990 77
1991 73
1992 69
1993 78
1994 73
1995 88
1996 93
1997 99
1998 95
1999 99
2000 134
2001 126
2002 141
2003 139
2004 130
2005 122
2006 143
2007 141
2008 136
2009 184
2010 198
2011 182
2012 218
2013 200
2014 194
2015 237
2016 268
2017 273
2018 315
2019 294
2020 355
2021 388
2022 401
2023 428
2024 424
2025 433
2026 225

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,374 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean masaki k[au] (729 results)?
Management of chronic myeloid leukemia in 2025.
Kantarjian H, Breccia M, Haddad FG, Hehlmann R, Issa GC, Malhotra H, Nicolini FE, Sasaki K, Stenke L, Jabbour E. Kantarjian H, et al. Among authors: sasaki k. Cancer. 2025 Jul 15;131(14):e35953. doi: 10.1002/cncr.35953. Cancer. 2025. PMID: 40616814 Free PMC article. Review.
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. DiNardo CD, et al. Among authors: sasaki k. Leukemia. 2025 Apr;39(4):854-863. doi: 10.1038/s41375-025-02531-8. Epub 2025 Feb 25. Leukemia. 2025. PMID: 40000842 Free PMC article. Clinical Trial.
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.
DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen WY, Daver NG, Reville PK, Short NJ, Sasaki K, Mullin JK, Bradley CA, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Abbas HA, Hammond DE, Haddad F, Bravo GM, Chien KS, Yilmaz M, Kornblau SM, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Konopleva MY, Kantarjian HM. DiNardo CD, et al. Among authors: sasaki k. J Clin Oncol. 2025 Aug 20;43(24):2692-2699. doi: 10.1200/JCO-25-00640. Epub 2025 Jun 13. J Clin Oncol. 2025. PMID: 40513054 Free PMC article.
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.
Mauro MJ, Minami Y, Hochhaus A, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Cortes JE, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Chee L, García-Gutiérrez V, Sasaki K, Boquimpani C, Kapoor S, Espurz N, Dhamal V, Rea D. Mauro MJ, et al. Among authors: sasaki k. Blood Adv. 2025 Aug 26;9(16):4248-4259. doi: 10.1182/bloodadvances.2025016042. Blood Adv. 2025. PMID: 40334072 Free PMC article. Clinical Trial.
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients.
Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, Carpentier B, Rausch C, Lebon D, Maiti A, Gauthier N, Short N, Bonnet S, Sasaki K, Khalife-Hachem S, Swaminathan M, Micol JB, Pasquier F, Marzac C, Roos-Weil D, Pascal L, Daver N, Kadia T, Bouscary D, Ravandi F, Pages A, Kantarjian H, De Botton S, DiNardo C. Willekens C, et al. Among authors: sasaki k. Blood Cancer J. 2025 Apr 17;15(1):68. doi: 10.1038/s41408-025-01269-x. Blood Cancer J. 2025. PMID: 40246832 Free PMC article.
Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements.
Bataller A, Goulart HE, Issa GC, DiNardo CD, Daver N, Kadia T, Bazinet A, Bouligny IM, Senapati J, Haddad FG, Borthakur G, Sasaki K, Short NJ, Yilmaz M, Montalban-Bravo G, Tang G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian H, Jabbour E. Bataller A, et al. Among authors: sasaki k. Leukemia. 2025 Jul;39(7):1640-1649. doi: 10.1038/s41375-025-02634-2. Epub 2025 May 9. Leukemia. 2025. PMID: 40346311
Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes.
Reville PK, Wang B, Marvin-Peek J, Yuan B, Kuo YA, Garza A, Root J, Qiao W, Arruda A, Veletic I, Liu Y, Short NJ, DiNardo CD, Kadia TM, Daver NG, Lorenzi PL, Sasaki K, Kornblau S, Minden MD, Ravandi F, Kantarjian HM, Abbas HA. Reville PK, et al. Among authors: sasaki k. Blood. 2025 Jun 19;145(25):3015-3029. doi: 10.1182/blood.2024027244. Blood. 2025. PMID: 40179376 Free PMC article.
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.
Raj R, Catueno S, Gibson A, McCall D, Garcia MB, Nunez C, Roth M, Sasaki K, Tewari P, Issa GC, Farhat A, Connors J, Sheikh I, Nishida Y, Yi JS, Stevens AM, Bataller A, Bhalla K, Petropoulos D, Daver N, Kadia T, Cuglievan B, DiNardo CD. Raj R, et al. Among authors: sasaki k. Blood. 2025 Nov 20;146(21):2608-2611. doi: 10.1182/blood.2025029391. Blood. 2025. PMID: 40971491
7,374 results